Solve

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Loading Image

Now I have all the material I need. Here are the complete, exam-ready answers:

ABVIMS & Dr. RML Hospital - OBG MBBS 3rd Year Exam Answers

Q1. Case: 34-year-old primigravida, 26 weeks gestation, 2-hr post 75g glucose = 190 mg/dL [25 marks]

Q1.1 - Probable Diagnosis [2 marks]

Gestational Diabetes Mellitus (GDM)

Using IADPSG (International Association of Diabetes and Pregnancy Study Groups) criteria - the cut-off for 2-hour post-load glucose after a 75g OGTT is ≥153 mg/dL. This patient's value of 190 mg/dL clearly exceeds this threshold, confirming GDM.

(Note: A random plasma glucose ≥200 mg/dL would indicate overt diabetes - this patient falls in the GDM range.)

Q1.2 - Diagnostic Tests for GDM [3 marks]

Two major screening/diagnostic approaches:

A. One-Step Approach (IADPSG/WHO - widely used internationally):

Single 75g OGTT at 24-28 weeks (non-fasting not required, but fasting recommended)
GDM diagnosed if ANY ONE value is met:

Time point	Threshold
Fasting	≥ 92 mg/dL
1-hour post-load	≥ 180 mg/dL
2-hour post-load	≥ 153 mg/dL

B. Two-Step Approach (ACOG/US standard):

Step 1: 50g Glucose Challenge Test (GCT) - non-fasting, 1-hour value ≥140 mg/dL is positive
Step 2 (if GCT positive): 100g OGTT over 3 hours; GDM if 2 or more values are met (Carpenter-Coustan or NDDG criteria)

Additional investigations once GDM is diagnosed:

HbA1c (if elevated >6.5%, suggests pre-existing diabetes)
Fasting plasma glucose
Urine for glucose/ketones
Renal function tests (baseline)
Ophthalmologic evaluation (if pre-existing diabetes suspected)

Q1.3 - Maternal and Fetal Complications [4 marks]

Maternal Complications:

Short-term	Long-term
Preeclampsia / hypertension	T2DM (50% risk within 5-10 years)
Polyhydramnios	Recurrent GDM in future pregnancies
Increased risk of caesarean section	Cardiovascular disease
Urinary tract infections	Metabolic syndrome
Preterm labor
Shoulder dystocia (due to macrosomia)
HELLP syndrome
Postpartum hemorrhage

Fetal/Neonatal Complications:

Fetal	Neonatal
Macrosomia (birth weight >4 kg)	Neonatal hypoglycemia
Intrauterine growth restriction (in poorly managed cases)	Respiratory distress syndrome (RDS)
Stillbirth	Neonatal hyperbilirubinemia (jaundice)
Congenital anomalies (if pre-existing DM)	Polycythemia
Fetal distress / asphyxia	Hypocalcemia, hypomagnesemia
Increased risk of obesity/T2DM in offspring	Birth injuries (clavicle fracture, brachial plexus injury)

Q1.4 - Indications for Caesarean Section in GDM [4 marks]

GDM itself is not an absolute indication for CS, but the following are indications in this condition:

Obstetric indications specific to GDM:

Macrosomia - Estimated fetal weight >4,500 g (some guidelines use >4,000 g with poor glycemic control) - prophylactic CS to prevent shoulder dystocia
Previous caesarean section with macrosomic fetus
Shoulder dystocia in previous delivery
Cephalopelvic disproportion (CPD) - common due to large fetal size
Failed induction of labor - GDM patients are often induced at 38-39 weeks; if labor fails to progress, CS is indicated
Fetal distress intrapartum (non-reassuring CTG, abnormal FHR patterns)
Malpresentation (breech, transverse lie) - more common with macrosomia/polyhydramnios
Polyhydramnios causing cord prolapse or malpresentation
Pre-eclampsia with severe features requiring immediate delivery with an unfavorable cervix
Placenta previa (associated with GDM)
Previous uterine surgery / classical CS scar

Q1.5 - Medical Nutrition Therapy (MNT) and Its Basic Principles [6 marks]

Definition: Medical Nutrition Therapy is a structured dietary intervention prescribed and monitored by a registered dietitian/physician to manage blood glucose, provide adequate nutrition for fetal growth, and minimize maternal and neonatal complications in GDM.

Basic Principles of MNT in GDM:

Caloric requirements:
- Adequate calories to support fetal growth without promoting hyperglycemia
- Typically: 30-35 kcal/kg/day for normal BMI; 25 kcal/kg/day for overweight; 12-15 kcal/kg/day for obese women
- Total weight gain goal: 11-16 kg for normal BMI, 7-11 kg for overweight, 5-9 kg for obese
Carbohydrate restriction and distribution:
- Carbohydrates should constitute 33-40% of total calories (some guidelines: 40-45%)
- Carbohydrates are distributed across 3 main meals + 2-3 snacks to avoid postprandial glucose spikes
- Breakfast carbohydrates should be limited (15-30g) as insulin resistance is highest in the morning
- Emphasize complex carbohydrates with low glycemic index (whole grains, legumes, vegetables)
- Avoid simple sugars, refined carbohydrates, fruit juices, and sugar-sweetened beverages
Protein intake:
- 20% of total calories from protein
- Sources: lean meat, fish, eggs, legumes, dairy
Fat intake:
- 40% of total calories; emphasis on unsaturated fats
- Limit saturated fats and trans fats
Fiber:
- ≥28g/day recommended - slows glucose absorption, improves postprandial glycemia
Monitoring response:
- Blood glucose targets: Fasting <95 mg/dL, 1-hr postprandial <140 mg/dL, 2-hr postprandial <120 mg/dL
- Self-monitoring of blood glucose 4 times daily (fasting + post-meals)
- Urine ketones monitored to avoid starvation ketosis
Exercise:
- 30 minutes of moderate aerobic exercise (walking) after meals complements MNT
- Reduces insulin resistance and postprandial glucose levels

Q1.6 - Drugs Used to Treat GDM: Types, Onset, Duration [6 marks]

When MNT and lifestyle modification fail to achieve target glucose levels, pharmacotherapy is initiated.

A. INSULIN (Drug of Choice in GDM)

Type	Drug	Onset of Action	Peak	Duration
Rapid-acting	Insulin Lispro (Humalog)	15 min	30-90 min	3-5 hrs
Rapid-acting	Insulin Aspart (NovoLog)	10-20 min	40-50 min	3-5 hrs
Short-acting (Regular)	Regular Insulin (Actrapid)	30-60 min	2-4 hrs	5-8 hrs
Intermediate-acting	NPH (Isophane) Insulin	1-3 hrs	4-8 hrs	12-18 hrs
Long-acting	Insulin Glargine (Lantus)	2-4 hrs	Peakless	20-24 hrs
Long-acting	Insulin Detemir (Levemir)	1-2 hrs	6-8 hrs	17-24 hrs

Use in GDM:

Basal-bolus regimen: Long-acting insulin (glargine/detemir) once daily + rapid-acting (lispro/aspart) with meals
NPH + Regular insulin: Twice-daily "split-mixed" regimen (still widely used)
Insulin does NOT cross the placenta - hence safe for fetus

B. ORAL HYPOGLYCEMICS

Note: Use is controversial and off-label in many countries; not first-line in most guidelines, but used in some settings

Drug	Class	Onset	Duration	Notes
Metformin	Biguanide	2-3 hrs	8-12 hrs	Crosses placenta; reasonable safety data; reduces insulin resistance; may be used when patient refuses insulin
Glyburide (Glibenclamide)	Sulfonylurea	2-4 hrs	16-24 hrs	Crosses placenta (fetal hypoglycemia risk); higher failure rate; not preferred by ACOG

Starting thresholds for insulin: If fasting glucose consistently >95 mg/dL or 2-hr postprandial >120 mg/dL despite MNT for 1-2 weeks.

Q2. Short Notes [5 × 5 = 25 marks]

Q2.1 - POP-Q Classification for Prolapse [5 marks]

The Pelvic Organ Prolapse Quantification (POP-Q) system is the internationally standardized classification approved by the International Continence Society (ICS) for grading female pelvic organ prolapse.

Reference Point: The hymen is the fixed reference (= 0). Measurements proximal to the hymen are negative (-), distal are positive (+).

Nine Measurement Points:

POP-Q Diagram showing anatomical measurement sites Aa, Ba, C, D, Ap, Bp, gh, pb, tvl

Point	Location	Normal Value
Aa	Anterior vaginal wall, 3 cm proximal to external urethral meatus (bladder neck)	-3 cm
Ba	Most distal point of anterior vaginal wall (between Aa and cervix/cuff)	-3 cm
C	Cervix or vaginal cuff (post-hysterectomy)	Varies
D	Posterior fornix (omitted post-hysterectomy)	Varies
Ap	Posterior vaginal wall, 3 cm proximal to hymen	-3 cm
Bp	Most distal point of posterior vaginal wall (between Ap and cervix/cuff)	-3 cm
gh	Genital hiatus - from urethral meatus to posterior midline hymen	~2-3 cm
pb	Perineal body - from posterior margin of gh to mid-anal opening	~2-3 cm
tvl	Total vaginal length - greatest depth when apex is fully reduced	~8-10 cm

Staging (0 to IV):

Stage	Description
Stage 0	No prolapse; Aa, Ba, Ap, Bp all at -3 cm; C or D ≤ -(tvl-2) cm
Stage I	Most distal point of prolapse >1 cm above the hymen (< -1 cm)
Stage II	Most distal point within 1 cm of the hymen (-1 to +1 cm)
Stage III	Most distal point >1 cm below the hymen but protrudes less than (tvl-2) cm
Stage IV	Complete eversion/procidentia; most distal point ≥ (tvl-2) cm

Advantages over older systems:

Standardized, reproducible, quantitative measurements
Multiple vaginal compartments assessed simultaneously
Reference point (hymen) is constant and independent of patient position
Can track disease progression accurately over time

Q2.2 - Clinical Presentations of Fibroid Uterus and Management [5 marks]

Uterine fibroids (leiomyomas) are the most common benign tumors of the uterus, arising from smooth muscle cells.

Classification by location:

Submucosal - beneath endometrium, project into uterine cavity (most symptomatic)
Intramural - within the myometrium (most common)
Subserosal - beneath the serosa, project outward
Pedunculated - attached by a stalk (submucosal or subserosal)
Cervical - located in cervix
Broad ligament (parasitic) - in broad ligament

Clinical Presentations:

Abnormal uterine bleeding (AUB):
- Most common symptom, especially with submucosal fibroids
- Menorrhagia (heavy, prolonged periods), metrorrhagia
- Secondary iron-deficiency anemia, fatigue, pallor
Pelvic pressure/pain:
- Heaviness, dragging sensation in pelvis
- Dysmenorrhea (painful periods)
- Acute pain - torsion of pedunculated fibroid, red degeneration (in pregnancy)
- Chronic pelvic pain
Pressure symptoms:
- Urinary: Frequency, urgency, retention, hydroureter (anterior fibroid pressing on bladder)
- Bowel: Constipation, tenesmus (posterior fibroid pressing on rectum)
Infertility and reproductive problems:
- Submucosal fibroids distort the uterine cavity and impair implantation
- Recurrent miscarriage
- Obstruction of fallopian tube ostia
Abdominal mass:
- Firm, irregular, non-tender enlarged uterus palpable abdominally when fibroids are large
Pregnancy complications:
- Red degeneration (carneous degeneration) - acute painful episode in pregnancy
- Malpresentation, obstructed labor
- Postpartum hemorrhage

Management:

A. Conservative (Asymptomatic / small fibroids):

Regular monitoring with pelvic ultrasound every 6-12 months
Observation especially in perimenopausal women (fibroids shrink after menopause)

B. Medical Management:

GnRH agonists (Leuprolide, Goserelin): Reduce fibroid size by 30-50%; used preoperatively; max 6 months (bone loss risk)
Progesterone receptor modulators (Ulipristal acetate): Reduces bleeding and fibroid size
Levonorgestrel IUS (Mirena): Controls menorrhagia with intramural/small submucosal fibroids
Combined OCP / progestins: Control bleeding, not fibroid size
Tranexamic acid / NSAIDs: Symptomatic relief of menorrhagia/dysmenorrhea
Iron supplementation: For anemia

C. Surgical Management:

Myomectomy (fibroid removal with uterine preservation): For women desiring future fertility; can be done hysteroscopically (submucosal), laparoscopically, or via laparotomy
Hysterectomy (definitive cure): For women who have completed childbearing with severe symptoms
Hysteroscopic resection: Best for submucosal fibroids (type 0, 1, 2)

D. Minimally Invasive / Radiological:

Uterine Artery Embolization (UAE): Blocks blood supply to fibroids; good for symptomatic women who want to avoid surgery; not recommended if future fertility is desired
MRI-guided Focused Ultrasound (MRgFUS): Non-invasive ablation; suitable for selected cases

Q2.3 - Eclampsia Management [5 marks]

Definition: Eclampsia is the occurrence of grand mal seizures in a woman with preeclampsia, not attributable to other causes.

Immediate Management (ABC approach):

Step 1 - Secure Airway and Prevent Injury:

Place patient in left lateral position
Padded side-rails; bite block if safe
Suction oropharynx; administer oxygen (6-8 L/min by face mask)
Establish IV access (two large-bore IVs)

Step 2 - Control Seizures (MAGNESIUM SULFATE - drug of choice):

Loading dose: 4-6 g IV in 100 mL normal saline over 15-20 minutes
Maintenance dose: 2 g/hour by IV infusion
Monitor for magnesium toxicity (check every 1-2 hours):
- Urine output >25 mL/hr (must be maintained)
- Patellar/knee reflexes present (lost at ~7-10 mg/dL)
- Respiratory rate >12/min (depression at ~12 mg/dL)
- Serum Mg2+ if needed (therapeutic range: 4-7 mg/dL)
Antidote for Mg toxicity: Calcium gluconate 1g IV slowly

If seizures recur despite magnesium: Additional 2g Mg bolus IV; alternatively diazepam, phenytoin, or thiopentone

Step 3 - Control Hypertension:

Target: systolic <160 mmHg, diastolic <105 mmHg
Hydralazine: 5-10 mg IV push, repeat every 20-30 min (first-line)
Labetalol: 20 mg IV bolus, repeat every 10 min up to 300 mg total
Nifedipine: 10-20 mg oral (sublingual avoided - precipitous drop)
Avoid diuretics and hyperosmotic agents (worsen intravascular depletion)

Step 4 - Investigations:

CBC, platelet count (rule out HELLP syndrome)
LFTs, serum creatinine, uric acid
Urine protein (24-hr or spot protein:creatinine ratio)
Coagulation profile (PT, aPTT, fibrinogen)
CT head if: decreased consciousness, persistent seizures, lateralizing signs
Fetal monitoring: CTG, BPP, Doppler

Step 5 - Fluid Management:

Restrict IV fluids to 80-100 mL/hr (oliguria expected; avoid pulmonary edema)
Maintain urine output >25-30 mL/hr
Foley catheter for strict I/O monitoring

Step 6 - Delivery (Definitive Treatment):

Eclampsia at any gestational age is an indication for delivery
Stabilize patient first (seizure control, BP control)
Mode of delivery: vaginal delivery preferred if cervix is favorable; CS for obstetric indications
After delivery: continue Mg sulfate for at least 24-48 hours postpartum

Postpartum care:

Continue antihypertensives as needed
Watch for late postpartum eclampsia (up to 4 weeks)
Counsel about recurrence risk (25% in subsequent pregnancies)

Q2.4 - Balloon Tamponade [5 marks]

Definition: Balloon tamponade is a mechanical, minimally invasive method used to control postpartum hemorrhage (PPH) by inserting an inflatable balloon into the uterine cavity to exert direct pressure on bleeding sinusoids.

Principle: Applies intrauterine pressure exceeding the arterial perfusion pressure, thereby tamponading bleeding vessels - particularly effective for uterine atony (most common cause of PPH).

Indications:

Uterine atony not responding to uterotonics (oxytocin, ergometrine, carboprost)
Low-lying placenta / placenta previa with bleeding after delivery
Step-up in conservative PPH management (after uterotonics, before surgical intervention)
"Tamponade test" - if balloon controls bleeding, avoids need for surgery/embolization

Types of Balloons:

Device	Capacity	Notes
Bakri balloon	Up to 500-800 mL	Purpose-designed for PPH; has drainage channel to monitor ongoing bleeding
BT-Cath (Balloon Tamponade Catheter)	Up to 500 mL	Dual-channel design
Sengstaken-Blakemore tube	Modified use	Originally for esophageal varices
Condom catheter	Variable	Low-cost improvised device; widely used in resource-limited settings (e.g., condom tied over Foley catheter)
Foley catheter	30-80 mL	For minor bleeding, especially at lower segment/placenta bed

Procedure (Bakri Balloon):

Examine for lacerations and repair them first
Insert balloon transcervically into uterine cavity under ultrasound guidance
Inflate with warm normal saline (typically 250-500 mL) until bleeding stops ("tamponade test")
Leave inflated for 12-24 hours
Oxytocin infusion continued during balloon placement
Deflate gradually after 12-24 hours; monitor for rebleeding
If tamponade test negative (bleeding continues despite inflation) - proceed to surgical intervention (B-Lynch suture, devascularization, or hysterectomy)

Advantages:

Simple, quick, does not require general anesthesia
Preserves uterus and fertility
Buys time for resuscitation, transfer, or arranging definitive care
Effective in 70-90% of uterine atony cases

Contraindications:

Infection / chorioamnionitis (relative)
Uterine rupture (primary surgical repair needed)
Cervical/vaginal lacerations (must be repaired first)

Part of the "HAEMOSTASIS" stepwise algorithm: Balloon tamponade comes after uterotonics and before surgical steps.

Q2.5 - Management of HIV-Positive Mother During Labour [5 marks]

The goals of management are: prevent mother-to-child transmission (MTCT), protect healthcare workers, and ensure safe delivery for mother and baby.

MTCT occurs in 3 phases: Antepartum (25%), intrapartum (60-70%), postpartum via breastfeeding (15%).

A. Antiretroviral Therapy (ART) During Labour:

All HIV-positive pregnant women should be on combination ART (cART) throughout pregnancy, labor, and postpartum (regardless of CD4 count) - "Option B+" (WHO recommendation)
Standard regimen: TDF (Tenofovir) + 3TC (Lamivudine) + EFV (Efavirenz) - continued throughout labor
If woman presents in labor NOT on ART (unbooked case):
- Give single-dose Nevirapine (sdNVP) 200 mg orally immediately
- Add AZT (Zidovudine) + 3TC orally during labor
- Continue postpartum ART
If woman has high viral load (>1000 copies/mL) at time of delivery despite ART:
- IV Zidovudine infusion during labor (loading 2 mg/kg over 1 hr, then 1 mg/kg/hr until delivery) - recommended in some guidelines for high VL

B. Mode of Delivery:

Vaginal delivery is acceptable if: woman is on effective cART with viral load <50-200 copies/mL (undetectable) near term
Elective Caesarean section at 38 weeks is recommended if:
- Viral load >1000 copies/mL near term
- Not on ART / late presentation
- Coinfection with Hepatitis C (increases transmission risk)
- Previous infant with HIV infection

C. Intrapartum Precautions:

Minimize invasive procedures: Avoid fetal scalp electrodes, fetal blood sampling, artificial rupture of membranes (ARM) unless essential
If ARM required, delay as long as possible - prolonged rupture of membranes (>4 hours) increases MTCT risk
Avoid episiotomy unless absolutely necessary
Forceps/vacuum delivery: Use only for standard obstetric indications; instrumentation increases infant exposure to maternal blood
Universal precautions for all healthcare staff: double gloves, eye protection, safe sharps disposal

D. Third Stage Management:

Active management of third stage (oxytocin IM/IV) - standard
Ergometrine: caution with Protease Inhibitors (drug interaction - vasoconstriction); oxytocin preferred

E. Neonatal Prophylaxis (immediately after birth):

NVP syrup for the neonate: 2 mg/kg once daily for 6 weeks (standard prophylaxis)
If mother had undetectable viral load: 4 weeks NVP or AZT for neonate
If mother had high VL or no ART: Dual/Triple ART prophylaxis for neonate for 6 weeks

F. Infant Feeding:

In resource-rich settings: Avoid breastfeeding completely (formula feeding); eliminates postpartum transmission
In resource-limited settings (per WHO): Exclusive breastfeeding for 6 months with maternal ART (safer than mixed feeding); NVP prophylaxis for infant throughout breastfeeding
Virological testing of infant at: birth, 6 weeks, 6 months, and 18 months

G. Postpartum:

Continue maternal ART indefinitely (lifelong)
Contraception counseling
Screen for postnatal depression
HIV testing of partner

Sources: Creasy & Resnik's Maternal-Fetal Medicine (9780323828499); Berek & Novak's Gynecology (9781496380357); Rosen's Emergency Medicine (9780323757898); Sabiston Textbook of Surgery (9780443124341)

Reload

I'm ready! How can I help you?

Solve again

Here are the complete answers to the ABVIMS & Dr. RML Hospital OBG exam paper:

Q1. 34-year-old Primigravida, 26 weeks, 2-hr post 75g glucose = 190 mg/dL [25 marks]

Q1.1 - Probable Diagnosis [2 marks]

Gestational Diabetes Mellitus (GDM)

By IADPSG criteria, the 2-hour post-load glucose after a 75g OGTT cut-off for GDM is ≥153 mg/dL. This patient's value of 190 mg/dL clearly exceeds this, confirming GDM. (Overt diabetes would require ≥200 mg/dL random or fasting ≥126 mg/dL.)

Q1.2 - Diagnostic Tests for GDM [3 marks]

One-Step Approach (IADPSG/WHO - recommended internationally & in India)

A single 75g OGTT at 24-28 weeks - GDM is diagnosed if ANY ONE value is met:

Time Point	Threshold
Fasting	≥ 92 mg/dL
1-hour post-load	≥ 180 mg/dL
2-hour post-load	≥ 153 mg/dL

If any value meets the criteria for overt diabetes (fasting ≥126, 2-hr ≥200, random ≥200), it is classified as overt diabetes in pregnancy, not GDM.

Two-Step Approach (ACOG - USA)

Step 1: 50g Glucose Challenge Test (GCT), non-fasting; if 1-hr value ≥140 mg/dL → proceed to Step 2
Step 2: 100g 3-hour OGTT; GDM diagnosed if ≥2 values are abnormal (Carpenter-Coustan criteria: Fasting ≥95, 1-hr ≥180, 2-hr ≥155, 3-hr ≥140 mg/dL)

Additional Investigations (after diagnosis)

HbA1c: If ≥6.5%, suggests pre-existing (pregestational) diabetes
Fasting plasma glucose
Urine glucose and ketones
Renal function tests (baseline)
Fundoscopy (if pre-existing DM suspected)

Q1.3 - Maternal and Fetal Complications [4 marks]

Maternal Complications

Short-term	Long-term
Pre-eclampsia / hypertension	Type 2 DM (50% risk within 5-10 years)
Polyhydramnios	Recurrent GDM in future pregnancies
Increased caesarean rate	Metabolic syndrome
Urinary tract infections	Cardiovascular disease
Shoulder dystocia
Postpartum hemorrhage
Wound infection

Fetal and Neonatal Complications

Fetal	Neonatal
Macrosomia (birth wt >4 kg) - most common	Neonatal hypoglycemia
Intrauterine fetal death / stillbirth	Respiratory distress syndrome (RDS)
Congenital malformations (if pre-existing DM)	Neonatal hyperbilirubinemia (jaundice)
IUGR (in vascular disease)	Polycythemia
Fetal distress / birth asphyxia	Hypocalcemia, hypomagnesemia
Malpresentation (due to polyhydramnios)	Birth injuries - clavicle fracture, Erb's palsy
	Long-term: obesity and T2DM in offspring

Q1.4 - Indications for Caesarean Section in GDM [4 marks]

GDM is not an absolute indication for CS, but the following situations in GDM mandate or strongly indicate it:

Macrosomia - Estimated fetal weight >4,500g (some use >4,000g with poor glycemic control) to prevent shoulder dystocia
Cephalopelvic disproportion (CPD) - common due to fetal macrosomia
Failed induction of labor - GDM patients are often induced at 38-39 weeks; failure to progress warrants CS
Fetal distress - non-reassuring CTG, late decelerations, abnormal biophysical profile
Malpresentation - breech, transverse lie (more common with polyhydramnios/macrosomia)
Previous CS with large baby or unfavorable conditions for VBAC
Placenta previa (associated with GDM/obesity)
Pre-eclampsia with severe features requiring urgent delivery with unfavorable cervix
Cord prolapse (due to polyhydramnios)
Previous shoulder dystocia or birth injury in prior pregnancy
Maternal indications - severe uncontrolled DM with end-organ disease

Q1.5 - Medical Nutrition Therapy (MNT): Definition and Basic Principles [6 marks]

Definition

Medical Nutrition Therapy is a structured, individualized dietary intervention prescribed and monitored by a physician/registered dietitian to achieve target blood glucose levels, provide adequate nutrition for fetal growth, and prevent maternal and neonatal complications in GDM - without causing starvation ketosis.

Basic Principles

1. Caloric Requirements

Normal BMI: 30-35 kcal/kg ideal body weight/day
Overweight (BMI 25-29.9): 25 kcal/kg/day
Obese (BMI ≥30): 12-15 kcal/kg/day (caloric restriction to 1,600-1,800 kcal/day)
Minimum 1,800 kcal/day recommended in most guidelines to avoid ketosis
Total gestational weight gain goal: 11-16 kg (normal BMI), 7-11 kg (overweight), 5-9 kg (obese)

2. Carbohydrate Restriction and Distribution

Carbohydrates: 33-40% of total daily calories (max 45%)
Distribute across 3 main meals + 2-3 snacks to prevent postprandial spikes
Breakfast carbs should be lowest (15-30g) - insulin resistance is maximal in the morning
Choose complex carbs with low glycemic index: whole grains, legumes, vegetables, oats
Strictly avoid: simple sugars, refined flour, fruit juices, sugar-sweetened beverages, white rice

3. Protein

20% of total calories from protein
Sources: lean meats, fish, eggs, pulses, low-fat dairy

4. Fat

40% of total calories; favor monounsaturated and polyunsaturated fats
Limit saturated fats and eliminate trans fats

5. Dietary Fiber

≥28g/day recommended
Slows glucose absorption, reduces postprandial glycemia, improves satiety

6. Blood Glucose Monitoring Targets

Fasting: <95 mg/dL
1-hour postprandial: <140 mg/dL
2-hour postprandial: <120 mg/dL
Self-monitoring 4 times daily (fasting + after each meal)
Urine ketones checked daily (morning) to detect starvation ketosis

7. Timing and Frequency of Meals

Never skip meals; regular intervals (every 3-4 hours)
Bedtime snack (25g carbs + protein) to prevent overnight fasting hypoglycemia and ketosis

8. Exercise as Adjunct

30 minutes of brisk walking or moderate aerobic exercise after meals
Reduces postprandial glucose and insulin resistance

Q1.6 - Drugs for GDM: Types, Onset, Duration [6 marks]

Pharmacotherapy is started when MNT fails to achieve targets for 1-2 weeks.

A. INSULIN - Drug of Choice in GDM

Insulin does not cross the placenta at therapeutic doses - it is the safest option.

Category	Drug	Onset	Peak	Duration
Ultra-rapid acting	Insulin Lispro (Humalog)	5-15 min	30-90 min	3-5 hours
Ultra-rapid acting	Insulin Aspart (NovoLog)	10-20 min	40-50 min	3-5 hours
Short-acting (Regular)	Regular Insulin (Actrapid/Humulin R)	30-60 min	2-4 hours	5-8 hours
Intermediate-acting	NPH / Isophane Insulin (Humulin N)	1-3 hours	4-8 hours	12-18 hours
Long-acting	Insulin Glargine (Lantus)	2-4 hours	Peakless (flat)	20-24 hours
Long-acting	Insulin Detemir (Levemir)	1-2 hours	6-8 hours	17-24 hours

Common regimens in GDM:

Twice-daily split-mixed: NPH + Regular (morning and evening) - widely used in India
Basal-bolus: Long-acting (Glargine once daily) + Rapid-acting (Lispro/Aspart before meals)
Insulin doses are adjusted based on blood glucose logs

B. ORAL HYPOGLYCEMIC AGENTS (off-label/second-line in most guidelines)

Drug	Class	Mechanism	Onset	Duration	Key Note
Metformin	Biguanide	Reduces hepatic glucose production, improves insulin sensitivity	2-3 hrs	8-12 hrs	Crosses placenta; reasonable safety data; used when patient refuses insulin; may be used as adjunct
Glyburide (Glibenclamide)	Sulfonylurea (2nd gen)	Stimulates pancreatic insulin secretion	2-4 hrs	16-24 hrs	Crosses placenta - neonatal hypoglycemia risk; higher failure rate; NOT preferred by ACOG; rarely used now

Threshold to initiate pharmacotherapy:

Fasting glucose consistently >95 mg/dL, OR
2-hr postprandial consistently >120 mg/dL despite 1-2 weeks of MNT

Q2. Short Notes [5 × 5 = 25 marks]

Q2.1 - POP-Q Classification for Prolapse [5 marks]

The Pelvic Organ Prolapse Quantification (POP-Q) system is the standardized classification approved by the International Continence Society (ICS) for quantifying female pelvic organ prolapse.

Reference Point

The hymen is the fixed anatomical landmark (= 0 cm). Points proximal to hymen = negative values; points distal to hymen = positive values. All measurements taken at maximal Valsalva (straining), except total vaginal length.

The 9 Measurement Points

Point	Compartment	Location	Normal Value
Aa	Anterior	3 cm proximal to external urethral meatus (= bladder neck)	-3 cm
Ba	Anterior	Most distal point of anterior vaginal wall (Aa to cervix/cuff)	-3 cm
C	Apical	Leading edge of cervix (or vaginal cuff post-hysterectomy)	Variable
D	Apical	Posterior fornix / pouch of Douglas (omitted post-hysterectomy)	Variable
Ap	Posterior	3 cm proximal to hymen on posterior vaginal wall	-3 cm
Bp	Posterior	Most distal point of posterior wall (Ap to cervix/cuff)	-3 cm
gh	-	Genital hiatus: mid-urethral meatus to posterior midline hymen	~2-3 cm
pb	-	Perineal body: posterior margin of gh to mid-anal opening	~2-3 cm
tvl	-	Total vaginal length: greatest depth with apex fully reduced	~8-10 cm

POP-Q Staging (based on most advanced point of prolapse)

Stage	Criteria
Stage 0	No prolapse; all points at -3 cm; C/D ≤ -(tvl-2) cm
Stage I	Most distal point > 1 cm above hymen (< -1 cm)
Stage II	Most distal point within 1 cm of hymen (-1 to +1 cm)
Stage III	Most distal point > 1 cm below hymen but < (tvl-2) cm
Stage IV	Complete eversion; most distal point ≥ (tvl-2) cm

Advantages Over Older Systems (Baden-Walker)

Quantitative, reproducible measurements at a fixed reference point (hymen)
Assesses all three vaginal compartments simultaneously
Can track progression over time and in research studies
Standardized across centers globally

Q2.2 - Clinical Presentations of Fibroid Uterus and Management [5 marks]

Uterine fibroids (leiomyomas) are the most common benign smooth muscle tumors of the uterus.

Types by Location

Submucosal (beneath endometrium - most symptomatic for bleeding)
Intramural (within myometrium - most common)
Subserosal (beneath uterine serosa - pressure symptoms)
Pedunculated (on a stalk - torsion risk)
Cervical and Broad ligament (parasitic)

Clinical Presentations

1. Abnormal Uterine Bleeding (AUB)

Menorrhagia (heavy, prolonged periods) - especially submucosal fibroids
Metrorrhagia, intermenstrual spotting
Secondary iron-deficiency anemia (fatigue, pallor, dyspnea)

2. Pelvic Pain and Pressure

Heaviness, dragging pelvic discomfort
Dysmenorrhea
Acute pain: torsion of pedunculated fibroid, red (carneous) degeneration in pregnancy (most common cause of acute pain with fibroids in pregnancy)

3. Pressure Symptoms

Anterior fibroids: urinary frequency, urgency, incomplete voiding, retention
Posterior fibroids: constipation, tenesmus
Large fibroids: venous compression causing lower limb edema, varicosities

4. Abdominal Mass

Hard, irregular, non-tender, mobile uterine mass palpable abdominally when fibroids are large (>12-14 weeks size)

5. Infertility and Pregnancy Loss

Submucosal fibroids distort the cavity, impair implantation, and cause recurrent miscarriage
Intramural fibroids may obstruct tubal ostia

6. Complications in Pregnancy

Malpresentation (breech, transverse), obstructed labor
Preterm labor, IUGR, placental abruption
PPH (uterine atony from large fibroids)

Management

A. Conservative / Expectant

Asymptomatic fibroids, small size, perimenopausal women (fibroids regress after menopause)
6-12 monthly ultrasound surveillance

B. Medical

Drug	Mechanism	Use
GnRH agonists (Leuprolide, Goserelin)	Hypo-oestrogenic state; shrinks fibroid 30-50%	Pre-op to reduce size; max 6 months
Progesterone receptor modulators (Ulipristal acetate)	Reduces bleeding + fibroid size	Intermittent medical treatment
Levonorgestrel IUS (Mirena)	Local progestogen; reduces bleeding	For menorrhagia with small/intramural fibroids
Combined OCP / Progestins	Reduce menstrual flow	Symptomatic relief only
Tranexamic acid, NSAIDs	Antifibrinolytic; antiprostaglandin	Acute menorrhagia control
Iron supplementation	Corrects anemia	Adjunct

C. Surgical

Hysteroscopic myomectomy: Submucosal fibroids (FIGO type 0, 1, 2) - preserves uterus; best for fertility
Laparoscopic myomectomy: Small-medium intramural/subserosal fibroids - minimally invasive
Open myomectomy (laparotomy): Large, multiple, or deep intramural fibroids; fertility preserving
Hysterectomy: Definitive cure; for women who have completed family; total abdominal, vaginal, or laparoscopic

D. Minimally Invasive / Interventional Radiology

Uterine Artery Embolization (UAE): Occludes uterine arteries; 85-90% success for symptom control; not for those desiring fertility
MRI-guided Focused Ultrasound (MRgFUS): Non-invasive thermal ablation; suitable for selected symptomatic fibroids

Q2.3 - Eclampsia Management [5 marks]

Definition: Grand mal seizures in a woman with pre-eclampsia, not attributable to other causes (epilepsy, hypoglycemia, etc.)

Immediate Steps (ABCDE)

Step 1 - Airway and Safety

Left lateral position (reduces aspiration, relieves aortocaval compression)
Airway secured; oxygen 8-10 L/min by face mask
Suction oropharynx; padded side-rails
IV access - two large-bore cannulas

Step 2 - Terminate Seizures: MAGNESIUM SULFATE (Drug of Choice)

Loading dose: 4-6g IV in 100 mL NS over 15-20 minutes
Maintenance: 2g/hour by continuous IV infusion
Continue for 24-48 hours after delivery or last seizure (whichever is later)

Monitoring for Mg toxicity (every 1-2 hours):

Parameter	Action
Urine output	Must be >25 mL/hr; if <25 mL/hr, reduce infusion
Patellar reflexes	Must be present; loss occurs at Mg ~7-10 mg/dL
Respiratory rate	Must be >12/min; depression at Mg ~12 mg/dL
Serum Mg	Therapeutic range: 4-7 mg/dL

Antidote: Calcium gluconate 1g IV slowly (over 10 min) for toxicity

Recurrent seizures: Additional 2g Mg IV bolus; or diazepam 10mg IV; or phenytoin

Step 3 - Control Blood Pressure

Target: systolic <160 mmHg, diastolic <105-110 mmHg
Hydralazine: 5-10 mg IV, repeat every 20-30 min (first-line parenteral)
Labetalol: 20 mg IV bolus, double dose every 10 min (max 300 mg total)
Nifedipine: 10-20 mg oral, repeat in 30 min if needed (oral only - not sublingual)
Avoid diuretics (worsen intravascular volume depletion)

Step 4 - Investigations

CBC, platelets (rule out HELLP: H-hemolysis, EL-elevated liver enzymes, LP-low platelets)
LFTs, serum creatinine, uric acid
Coagulation profile (PT, aPTT, fibrinogen)
24-hr urine protein
CTG + BPP for fetal wellbeing
CT head if: prolonged unconsciousness, focal neurological signs, recurrent seizures

Step 5 - Fluid Management

Restrict to 80-100 mL/hr total IV fluid input
Foley catheter; strict intake-output monitoring
Maintain urine output >25-30 mL/hr

Step 6 - Delivery (Definitive Treatment)

Eclampsia at ANY gestational age = indication for delivery after stabilization
Vaginal delivery preferred if cervix is favorable and maternal/fetal condition stable
CS for standard obstetric indications
Continue Mg sulfate through labor and for 24-48 hours postpartum

Postpartum:

Antihypertensives continued (methyldopa, labetalol, nifedipine)
Watch for late postpartum eclampsia (up to 4 weeks post-delivery)
Counseling: 25% recurrence risk in subsequent pregnancies; long-term cardiovascular risk

Q2.4 - Balloon Tamponade [5 marks]

Definition

Balloon tamponade is a minimally invasive, uterus-preserving mechanical method to control postpartum hemorrhage (PPH) by placing an inflatable balloon in the uterine cavity to exert direct hydrostatic pressure on bleeding sinusoids.

Principle

The inflated balloon generates intrauterine pressure exceeding the local arterial perfusion pressure, physically tamponading the bleeding vessels - most effective for uterine atony (responsible for 80% of PPH).

Indications

Uterine atony not controlled by uterotonics (oxytocin, ergometrine, carboprost, misoprostol)
PPH secondary to placenta previa / low-lying placenta (after placenta delivered)
Placenta accreta spectrum (temporizing measure)
As a "tamponade test": if balloon controls bleeding, avoids need for surgical/radiological intervention
Step in the stepwise management of PPH (after uterotonics, before B-Lynch/hysterectomy)

Types of Balloon Devices

Device	Fill Volume	Feature
Bakri balloon	Up to 500-800 mL	Purpose-designed; drainage channel monitors ongoing bleeding
BT-Cath	Up to 500 mL	Dual-channel system
Sengstaken-Blakemore tube	Modified use	Original use: esophageal varices; used in emergency
Condom catheter	Variable	Low-cost, widely used in resource-limited settings (condom tied to Foley catheter)
Foley catheter balloon	30-80 mL	For minor lower segment bleeding

Procedure (Bakri Balloon)

Inspect and repair all cervical and vaginal lacerations first
Insert balloon into uterine cavity transcervically (manual or under ultrasound guidance)
Inflate with warm normal saline (typically 250-500 mL, guided by cessation of bleeding)
Tamponade test: if bleeding stops = tamponade successful; if persists = surgical step needed
Secure catheter to thigh; leave inflated for 12-24 hours
Continue oxytocin infusion while balloon is in situ
Uterine compression sutures + balloon together = "uterine sandwich" (for atony)
Deflate gradually under observation; monitor for rebleeding

Advantages

Quick, simple; no general anesthesia needed
Preserves uterus and future fertility
Effective in 70-90% of uterine atony cases
Buys time for resuscitation, transfer, or definitive care
Can be used at peripheral centers while awaiting transfer

Contraindications

Uterine rupture (needs immediate surgical repair)
Uterine infection / chorioamnionitis (relative)
Must repair lacerations before placement

Place in the HAEMOSTASIS Algorithm

Q2.5 - Management of HIV-Positive Mother During Labour [5 marks]

The three goals are: prevent mother-to-child transmission (MTCT), ensure safe delivery, and protect healthcare workers.

MTCT risk breakdown:

Antenatal: 25% | Intrapartum: 60-70% (highest risk) | Postnatal (breastfeeding): 15%
Without any intervention: MTCT rate ~25-45%; with optimal ART: <1-2%

A. Antiretroviral Therapy (ART) During Labour

Women already on ART (Option B+):

Continue combination ART (cART) throughout labor: standard regimen = TDF + 3TC + EFV (Tenofovir + Lamivudine + Efavirenz) - taken orally
Do NOT stop ART at any point during labor

Woman presents in labor WITHOUT prior ART (unbooked):

Give single-dose Nevirapine (sdNVP) 200 mg orally immediately
Add AZT (Zidovudine) 300 mg + 3TC (Lamivudine) 150 mg orally at onset of labor
Initiate lifelong cART postpartum

Woman with high viral load (>1,000 copies/mL) despite ART:

Consider IV Zidovudine infusion: loading 2 mg/kg over 1 hour, then 1 mg/kg/hour until delivery

B. Mode of Delivery

Viral Load Status	Recommended Mode
Undetectable (<50-200 copies/mL) on cART	Vaginal delivery acceptable
VL >1,000 copies/mL at 36 weeks	Elective CS at 38 weeks
Not on ART / late booking	Elective CS at 38 weeks
Coinfection with Hepatitis C	Elective CS (increased transmission risk)

C. Intrapartum Precautions

Minimize invasive procedures that expose baby to maternal blood:
- Avoid fetal scalp electrode (FSE), fetal blood sampling (FBS)
- Avoid artificial rupture of membranes (ARM) unless essential - prolonged ROM >4 hours increases MTCT
- If ARM needed, perform as close to delivery as possible
Avoid episiotomy unless absolutely necessary
Instrumental delivery (forceps/vacuum): only for standard obstetric indications; minimize time
Universal precautions for all staff: double gloves, eye protection, face shield, safe sharps disposal

D. Third Stage

Oxytocin preferred over ergometrine (ergometrine interacts with protease inhibitors - severe vasoconstriction risk)
Active management of third stage otherwise standard

E. Neonatal Prophylaxis (immediately post-delivery)

Maternal Status	Neonatal Prophylaxis
On ART, undetectable VL	NVP syrup 2 mg/kg once daily for 4-6 weeks
Not on ART / high VL	Dual/triple ART for infant: AZT + NVP for 6 weeks
Unknown HIV status	Test mother stat; treat infant empirically if high risk

Baby should be bathed immediately after delivery to remove maternal blood/secretions.

F. Infant Feeding

Resource-rich settings: Complete avoidance of breastfeeding; exclusive formula feeding (eliminates postnatal MTCT)
Resource-limited settings (WHO): Exclusive breastfeeding for 6 months with maternal cART + infant NVP prophylaxis (safer than mixed feeding)
Never mix breastfeeding and formula ("mixed feeding" greatly increases transmission risk)

G. Infant Follow-up

HIV virological testing (PCR): at birth, 6 weeks, 6 months, 18 months
If any test positive: start infant on cART immediately

H. Postpartum Maternal Care

Continue lifelong cART (regardless of CD4 count)
Contraception counseling (avoid OCP if on enzyme-inducing ARVs; IUCD or barrier methods preferred)
Screen for postnatal depression
Partner testing and counseling

Sources: Creasy & Resnik's Maternal-Fetal Medicine; Berek & Novak's Gynecology; Rosen's Emergency Medicine; Sabiston Textbook of Surgery

This is a shared conversation. Sign in to Orris to start your own chat.